Investigating the Impact of Proactive Palliative Care

Inclusion Criteria:

- Patients with disease progression on at least one standard chemotherapy regimen, and
now eligible and consented to begin Phase I, Phase I/Ib, and Phase I/II
investigational targeted and immune-based therapeutics in MSK medical oncology, EDD,
or ITC clinics

- Able to speak, read, and understand English well enough to complete study assessments
in the judgment of the consenting professional

- 18 years of age and older

- Has a progressive or metastatic solid tumor cancer with MSK pathology confirmation at
the primary or metastatic anatomic site

Exclusion Criteria:

- Patients who already are receiving specialty supportive care (already referred for a
supportive care consultation) prior to enrollment in a Phase I protocol.

- Patients will be excluded if the Phase I, Phase I/Ib, or Phase I/II trial involves
known active drugs in combination with experimental drugs, in which the patient has
not previously received the known active drug or active drugs of the same class. For
example, a patient with metastatic pancreatic cancer who has not received
gemcitabine/nab-paclitaxel, but enrolls on a study that tests an experimental drug in
addition to gemcitabine/nab-paclitaxel, will be excluded.

- Significant psychiatric or cognitive disturbance in the primary clinician‟s or
investigator‟s judgment, to preclude providing informed consent or participating in
the interventions (i.e. acute psychiatric symptoms which require individual treatment)